brimonidine-tartrate--timolol-maleate-drug-combination and Glaucoma

brimonidine-tartrate--timolol-maleate-drug-combination has been researched along with Glaucoma* in 3 studies

Reviews

1 review(s) available for brimonidine-tartrate--timolol-maleate-drug-combination and Glaucoma

ArticleYear
[The latest developments in glaucoma therapy using fixed combination products].
    Oftalmologia (Bucharest, Romania : 1990), 2011, Volume: 55, Issue:3

    Modern fixed-combination products simplify medication dose regimen without sacrificing their effectiveness.Potential benefits of the therapy with fixed-combination products are enhanced tolerability increased convenience,better compliance,cost and time economy and removal of the wash out effect. Regarding intraocular pressure lowering effect, fixed-combination agents are superior to monotherapy with the two medication components, with the exception of Duotrav that is not superior to travoprost action.Fixed-combination products are noninferior to concomitant administration of the two components of medication (nonfixed-combination agents) relative to their ocular hypotensive efficacy with the exception of Ganfort that is however inferior to concurrent administration of both the bimatoprost and timolol.

    Topics: Amides; Antihypertensive Agents; Bimatoprost; Brimonidine Tartrate, Timolol Maleate Drug Combination; Carbonic Anhydrase Inhibitors; Cloprostenol; Drug Combinations; Drug Therapy, Combination; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiazines; Thiophenes; Timolol; Travoprost; Treatment Outcome

2011

Other Studies

2 other study(ies) available for brimonidine-tartrate--timolol-maleate-drug-combination and Glaucoma

ArticleYear
Assessment of corneal sublayer thickness changes in glaucoma patients using optical coherence tomography and correlation of epithelial layer thinning with dry eye monitoring.
    Photodiagnosis and photodynamic therapy, 2023, Volume: 43

    In this study, we aimed to assess the central corneal epithelial thickness (CET), central corneal stromal thickness (CST), and total central corneal thickness (CCT) thinning relationships with dry eye development monitoring and underestimated measurement of intraocular pressure (IOP) in primary open-angle glaucoma (POAG) patients treated with timolol, dorzolamide, and brimonidine.. This longitudinal cohort study included 106 patients with POAG. All patients underwent a detailed ophthalmic examination. In addition, CET, CST, and CCT were measured using anterior segment optical coherence tomography (AS-OCT). Subsequently, the cohort was divided into three groups based on the therapy administered. The Tomec group received monotherapy with benzalkonium chloride (BAK)-preserved timolol + dorzolamide fixed combination. The Alphagan group received monotherapy with purite-preserved brimonidine, and the Combigan group received monotherapy with BAK-preserved timolol + brimonidine fixed combination.. CET, CST, and CCT did not show a statistically significant decrease in the Alphagan group (p>0.05). However, the Tomec and Combigan groups showed significantly reduced measurements, except for stromal thickness (p<0.05). Finally, a significant positive correlation was found between changes in tear break-up time (TBUT) and CET during the follow-up period (r = 0.637, p = 0.001).. CET and CCT thinning were higher in the Tomec and Combigan groups than in the Alphagan group. Furthermore, although CCT reduction was significant in the Tomec and Combigan groups, its effect on IOP underestimation was approximately 1%. Furthermore, the positive correlation between CET and TBUT suggests that CET measurement with AS-OCT may also be useful in dry eye monitoring.

    Topics: Brimonidine Tartrate; Brimonidine Tartrate, Timolol Maleate Drug Combination; Dry Eye Syndromes; Glaucoma; Glaucoma, Open-Angle; Humans; Longitudinal Studies; Photochemotherapy; Photosensitizing Agents; Timolol; Tomography, Optical Coherence

2023
Evaluation of the anti-Acanthamoeba activity of two commercial eye drops commonly used to lower eye pressure.
    Experimental parasitology, 2017, Volume: 183

    Efficient treatments against Acanthamoeba Keratitis (AK), remains until the moment, as an issue to be solved due to the existence of a cyst stage which is highly resistant to most chemical and physical agents. In this study, two antiglaucoma eye drops were tested for their activity against Acanthamoeba. Moreover, this study was based on previous data which gave us evidence of a possible link between the absences of Acanthamoeba at the ocular surface in patients treated with beta blockers for high eye pressure both containing timolol as active principle. The amoebicidal activity of the tested eye drops was evaluated against four strains of Acanthamoeba using Alamar blue method. For the most active drug the cysticidal activity against A. castellanii Neff cysts and further experiments studying changes in chromatin condensation levels, in the permeability of the plasmatic membrane, the mitochondrial membrane potential and the ATP levels in the treated amoebic strains were done. Even though both eye drops were active against the different tested strains of Acanthamoeba, statistical analysis revealed that one of them (Timolol Sandoz) was the most effective one against all the tested strains presenting IC

    Topics: Acanthamoeba; Acanthamoeba Keratitis; Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antagonists; Analysis of Variance; Apoptosis; Brimonidine Tartrate; Brimonidine Tartrate, Timolol Maleate Drug Combination; Glaucoma; Inhibitory Concentration 50; Intraocular Pressure; Membrane Potential, Mitochondrial; Ophthalmic Solutions; Timolol

2017